TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12553178

Group type: EXPERIMENTAL
Intervention: Self-reported pesticide exposure among farmworkers
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Protective practices to keep pesticide residues out of the home
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Pesticide levels in urine and dust samples
Number of subjects: 571
Study: 10586004

Group type: EXPERIMENTAL
Intervention: dTpa vaccine
Number of subjects: 510

Group type: COMPARATOR
Intervention: Td vaccine with pa vaccine
Number of subjects: 510

Group type: COMPARATOR
Intervention: dTpa or Td
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: dTpa and pa vaccines
Number of subjects: 510
Study: 8915665

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (300 mg/day, at bedtime)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone (300 mg/day)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group (18 apparently healthy females, no interventions)
Number of subjects: 299
Study: 1888621

Group type: EXPERIMENTAL
Intervention: Diclofenac gel (1 g diclofenac/100 g, 80 mg three times daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diclofenac gel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diclofenac gel and Placebo gel
Number of subjects: 10
Study: 3936085

Group type: EXPERIMENTAL
Intervention: 15 mg dextroamphetamine sulfate
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 22
Study: 30328781

Group type: EXPERIMENTAL
Intervention: Lavender oil applied on the face
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sunflower seed oil applied on the foot
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lavender oil applied on the foot
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sunflower seed oil applied on the face
Number of subjects: 42
Study: 28599060

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 400 mg once daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of sacubitril/valsartan and sildenafil
Number of subjects: 0
Study: 26975739

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Axillary dissection (ALND)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Overall Survival (OS)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Event-Free Survival (EFS)
Number of subjects: 225
Study: 24845606

Group type: EXPERIMENTAL
Intervention: Ballroom dancing program (3 sessions of 50 minutes each week for 12 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study: 22676908

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery for hematoma evacuation and the best medical treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment (the best medical treatment)
Number of subjects: 100
Study: 20810517

Group type: EXPERIMENTAL
Intervention: Treatment arms
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo groups
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Year of publication
Number of subjects: 32
Study: 23035962

Group type: EXPERIMENTAL
Intervention: Self-help cognitive behavioral intervention (CBT-I) with six booklets and telephone helpline
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Self-help cognitive behavioral intervention (CBT-I)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 193
Study: 15830639

Group type: EXPERIMENTAL
Intervention: SRP and 14% doxycycline gel (DOX)
Number of subjects: 110

Group type: COMPARATOR
Intervention: SRP with subgingival placebo gel (VEH)
Number of subjects: 110

Group type: COMPARATOR
Intervention: scaling and root planing (SRP) alone
Number of subjects: 110
Study: 11852170

Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2032
Study: 9614526

Group type: EXPERIMENTAL
Intervention: Visual field assessment with Goldmann perimetry
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Visual field assessment with Humphrey perimetry
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall visual status improvement
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Visual function assessment regime
Number of subjects: 35
Study: 8078164

Group type: EXPERIMENTAL
Intervention: Rapid test (30-minute enzyme immunoassay test and tissue culture)
Number of subjects: 1526

Group type: COMPARATOR
Intervention: Cell culture (routine screening clinic)
Number of subjects: 1526
Study: 2910293

Group type: EXPERIMENTAL
Intervention: Retrobulbar injections (5 mL)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Periocular injections (5 mL)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 79
Study: 5324105

Group type: EXPERIMENTAL
Intervention: dexamethasone-21-phosphate
Number of subjects: 200

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 200
Study: 28873284

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PRP injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 50
Study: 28749177

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure treatment target of 120 mmHg
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure treatment target of 120 mmHg in the lowest tertile of baseline systolic blood pressure
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Systolic blood pressure treatment target of 140 mmHg
Number of subjects: 9361
Study: 25074436

Group type: EXPERIMENTAL
Intervention: S100A12
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: sRAGE
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: S100A12/sRAGE ratio
Number of subjects: 200
Study: 23829576

Group type: EXPERIMENTAL
Intervention: Football group (FG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study: 21435016

Group type: EXPERIMENTAL
Intervention: Cresco components loaded 10 days post-implant placement
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cresco components loaded 6-8 weeks post-implant placement
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional components loaded 6-8 weeks post-implant placement
Number of subjects: 36
Study: 18226677

Group type: EXPERIMENTAL
Intervention: Carraguard gel
Number of subjects: 152
Study: 16458540

Group type: EXPERIMENTAL
Intervention: 60-Hz magnetic field exposure for 5 consecutive nights
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 0
Study: 12730861

Group type: EXPERIMENTAL
Intervention: VSL#3 (1 packet containing 900 billion bacteria/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 40
Study: 10919344

Group type: EXPERIMENTAL
Intervention: Flucozole (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diflucan (200 mg)
Number of subjects: 12
Study: 8977634

Group type: EXPERIMENTAL
Intervention: DC pulsed with PSM-P2 (group 5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DC pulsed with PSM-P1 (group 4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peptides alone (PSM-P1 or PSM-P2; groups 1 and 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous DC (group 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study: 3880556

Group type: EXPERIMENTAL
Intervention: Prednisone (10-15 mg daily)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488
Study: 31804571

Group type: EXPERIMENTAL
Intervention: Echocardiography (performed a median of 16 days following peritoneal dialysis initiation)
Number of subjects: 99
Study: 28495124

Group type: EXPERIMENTAL
Intervention: Visual demonstration of themselves as a lifelong smoker and non‐smoker
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard smoking cessation counselling sessions
Number of subjects: 98
Study: 26951242

Group type: EXPERIMENTAL
Intervention: Intensive Intervention Group (IIG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Minimal Intervention Group (MIG)
Number of subjects: 27
Study: 24394343

Group type: EXPERIMENTAL
Intervention: TRPV1 antagonist AZD1386
Number of subjects: 0
Study: 23095629

Group type: EXPERIMENTAL
Intervention: Pharmacological postconditioning with sevoflurane
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Intermittent clamping
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (continuous inflow occlusion)
Number of subjects: 115
Study: 20881647

Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 mg orally daily (after a loading dose) plus pemetrexed 500 mg/m², carboplatin AUC 6, and bevacizumab 15 mg/kg intravenously every 21 days for four cycles.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus pemetrexed 500 mg/m², carboplatin AUC 6, and bevacizumab 15 mg/kg intravenously every 21 days for four cycles.
Number of subjects: 40
Study: 18590751

Group type: EXPERIMENTAL
Intervention: Washing mouth with water
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Chewing to increase saliva volume
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Salivary proteins
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral mucosal wetness
Number of subjects: 15
Study: 15804153

Group type: EXPERIMENTAL
Intervention: PMEA (X-coating)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CTR (control)
Number of subjects: 60
Study: 12126042

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis patients (n=50)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients (n=25)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Normal controls (n=18)
Number of subjects: 93
Study: 7782179

Group type: EXPERIMENTAL
Intervention: non‐restricted diet of foods preselected and usually eaten by the child
Number of subjects: 100

Group type: COMPARATOR
Intervention: restricted diet of only soft foods and liquids
Number of subjects: 100
Study: 2169078

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin) at a dose of 75 U/kg/day for 5 days (I group, n = 27)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Fragmin) at a dose of 150 U/kg/day for 5 days (II group, n = 29)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified, but includes cases that died of underlying diseases or complications)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not specified, but includes cases with hemorrhagic side effects)
Number of subjects: 56
Study: 75391

Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flufenamic acid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dextropropoxyphene/paracetamol
Number of subjects: 30
Study: 31885120

Group type: EXPERIMENTAL
Intervention: Coping skills training (CST) + standard care (SC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 100
Study: 30860393

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous neuromodulation (PNM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 45

Group type: COMPARATOR
Intervention: Eccentric exercise
Number of subjects: 45
Study: 28017166

Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid injections
Number of subjects: 299

Group type: COMPARATOR
Intervention: Transforaminal epidural steroid injections
Number of subjects: 299
Study: 25942474

Group type: EXPERIMENTAL
Intervention: 7 mmol NO3(‐) supplementation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 24495046

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) for 5 days and rectal enema
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 50
Study: 22784287

Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch (HES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 25% human albumin (HA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ringer's solution (RS)
Number of subjects: 30
Study: 19960971

Group type: EXPERIMENTAL
Intervention: Yangyin Jiedu Huoxue Recipe (YJHR) plus conventional Western medical treatment
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional Western medical treatment only (Control)
Number of subjects: 78
Study: 17613964

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg per day
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 15645312

Group type: EXPERIMENTAL
Intervention: Gamma-ray exposure with an assumed neutron RBE of 35
Number of subjects: 0
Study: 12118271

Group type: EXPERIMENTAL
Intervention: Hypertonic/hyperoncotic solution
Number of subjects: 0
Study: 9094912

Group type: EXPERIMENTAL
Intervention: Cognitive-processing approach to self-reports of diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free and prompted report interviews conducted within 1.5 hours of lunch or the following morning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delphi technique study (future plan)
Number of subjects: 0
Study: 8426176

Group type: EXPERIMENTAL
Intervention: Innovative group and intensive case management program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual community mental health center and rehabilitation services
Number of subjects: 54
Study: 3305681

Group type: EXPERIMENTAL
Intervention: 15 mg/die methimazole (group A)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 30 mg/die methimazole (group B)
Number of subjects: 28
Study: 31887222

Group type: EXPERIMENTAL
Intervention: Oil-based contrast during HSG
Number of subjects: 400

Group type: COMPARATOR
Intervention: Water-based contrast during HSG
Number of subjects: 400
Study: 30062365

Group type: EXPERIMENTAL
Intervention: Long Live the Elderly program
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 207
Study: 27733248

Group type: EXPERIMENTAL
Intervention: Lower fat diet (20% energy, 65% carbohydrate)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Lower carbohydrate diet (45% energy, 35% fat)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Walnut-rich diet (18% energy, 35% fat, 45% carbohydrate)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Lower fat diet vs. lower carbohydrate diet (insulin sensitive women)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Walnut-rich diet vs. lower carbohydrate diet (insulin sensitive women)
Number of subjects: 245

Group type: COMPARATOR
Intervention: All groups (C-reactive protein and interleukin-6)
Number of subjects: 245

Group type: COMPARATOR
Intervention: All groups (Sex hormone binding globulin)
Number of subjects: 245
Study: 24077342

Group type: EXPERIMENTAL
Intervention: CODEX index
Number of subjects: 983
Study: 22565878

Group type: EXPERIMENTAL
Intervention: Rigid External Distractor (RED)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intraoral Appliance (IA)
Number of subjects: 8
Study: 20171784

Group type: EXPERIMENTAL
Intervention: 120 mg/day oral raloxifene hydrochloride
Number of subjects: 35

Group type: COMPARATOR
Intervention: 60 mg/day oral raloxifene hydrochloride
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 35
Study: 17324007

Group type: EXPERIMENTAL
Intervention: Cethromycin (ABT 773, A-195773, Abbott-195773, A-1957730, A-195773-0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cethromycin (ABT 773)
Number of subjects: 0
Study: 16133640

Group type: EXPERIMENTAL
Intervention: hPTH (1-34) 400 U/day (n=28)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (n=23)
Number of subjects: 51
Study: 14694042

Group type: EXPERIMENTAL
Intervention: Gabapentin (GPT) 2,400 mg/day
Number of subjects: 133
Study: 11068976

Group type: EXPERIMENTAL
Intervention: Extended 14‐session cognitive‐behavioral group treatment (RPSG)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Brief 2‐session individual treatment using motivational interviewing (IAI)
Number of subjects: 291

Group type: COMPARATOR
Intervention: 4‐month delayed treatment control (DTC)
Number of subjects: 291
Study: 8631163

Group type: EXPERIMENTAL
Intervention: 3000 IU bolus of heparin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 5000 IU bolus of heparin
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Monitoring of APTT values
Number of subjects: 55
Study: 1531927

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 6 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 12 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 24 weeks
Number of subjects: 120
Study: 3904398

Group type: EXPERIMENTAL
Intervention: Regimen A (vindesine, cis-platinum, and etoposide)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Regimen B (vindesine, cis-platinum, and lomustine)
Number of subjects: 37
Study: 3315585

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intravenous anisoylated plasminogen streptokinase activator complex (APSAC)
Number of subjects: 93
Study: 31776732

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study: 30807429

Group type: EXPERIMENTAL
Intervention: Colpassist
Number of subjects: 52

Group type: COMPARATOR
Intervention: EEAS
Number of subjects: 52
Study: 28380132

Group type: EXPERIMENTAL
Intervention: Resistance training (n = 32)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Aerobic training (n = 32)
Number of subjects: 69
Study: 25878124

Group type: EXPERIMENTAL
Intervention: Intervention involving the use of magnetic resonance imaging (MRI) to analyze blood flow and vascular deposition of circulating nanoparticles (NPs).
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Nanoparticles (NPs) targeted to inflammatory vascular molecules (VCAM‐1, E‐selectin, ICAM‐1).
Number of subjects: 1
Study: 24235952

Group type: EXPERIMENTAL
Intervention: 4mg ondansetron (Group O)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 8mg dexamethasone (Group D)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 4mg ondansetron + 8mg dexamethasone (Group OD)
Number of subjects: 90
Study: 21562990

Group type: EXPERIMENTAL
Intervention: Polypharmacy (using more than four medications)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: No medication review at baseline
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Medication review
Number of subjects: 457
Study: 19591338

Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride (CPC) mouthrinse
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control mouthrinse without CPC
Number of subjects: 110
Study: 16849762

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg bid with dexamethasone 4 mg daily
Number of subjects: 211

Group type: COMPARATOR
Intervention: ondansetron 8 mg bid with placebo
Number of subjects: 211
Study: 15327614

Group type: EXPERIMENTAL
Intervention: Metronidazole (1000 mg oral before abortion followed by 500 mg twice daily)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Metronidazole (among 153 women with Gram stain confirmation for bacterial vaginosis)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo (among 153 women with Gram stain confirmation for bacterial vaginosis)
Number of subjects: 393
Study: 10647523

Group type: EXPERIMENTAL
Intervention: Taped condition
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Untaped condition
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 25
Study: 9317068

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d., and metronidazole 500 mg b.i.d. (LCM) for 7 days
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d., and bismuth subsalicylate 524 mg b.i.d. (LCB) for 7 days
Number of subjects: 105
Study: 8403910

Group type: EXPERIMENTAL
Intervention: RU 486 (25, 100, 400, and 600 mg); single oral doses administered to pregnant women
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RU 486 (25, 100, 400, and 600 mg); single oral doses administered to non-pregnant women
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg); additional dose for 6 non-pregnant women
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RU 42633, RU 42848, RU 42698; metabolites of RU 486
Number of subjects: 45
Study: 2427458

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 200
Study: 30354310

Group type: EXPERIMENTAL
Intervention: Electrogram-based AVO (SmartDelay)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Nominal atrioventricular delay (120 ms)
Number of subjects: 275
Study: 27433065

Group type: COMPARATOR
Intervention: Chlorhexidine gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Curcumin gel
Number of subjects: 30
Study: 24788377

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study: 21993576

Group type: EXPERIMENTAL
Intervention: Small-wave incision method
Number of subjects: 40

Group type: COMPARATOR
Intervention: Linear incision method
Number of subjects: 40
Study: 20357310

Group type: EXPERIMENTAL
Intervention: Stepped care preventive intervention for depression and anxiety disorders
Number of subjects: 170

Group type: COMPARATOR
Intervention: Routine primary care
Number of subjects: 170
Study: 18510549

Group type: EXPERIMENTAL
Intervention: L-arginine (18 g daily for 6 months)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (18 g dextrose daily for 6 months)
Number of subjects: 23
Study: 15820455

Group type: EXPERIMENTAL
Intervention: Open lateral internal sphincterotomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chemical sphincterotomy with 25 U botulinum toxin
Number of subjects: 80
Study: 12583502

Group type: EXPERIMENTAL
Intervention: 4-week intensive outpatient program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 10357730

Group type: EXPERIMENTAL
Intervention: Physical training for 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical training for 4 months (after 4 months of no training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher pre-physical training concentrations of fibrinogen, PAI-1, and D-dimer
Number of subjects: 0